GKOS affiliate filed a Form 144 notice reporting proposed sales of restricted common stock. The notice lists a proposed sale tied to restricted stock vesting of 259 shares with an effective date of 12/27/2024 and 772 shares with an effective date of 01/01/2025.
Glaukos Corp's Chief Development Officer Tomas Navratil reported a small share disposal related to tax withholding. On March 5, 2026, 361 shares of common stock at $112.10 per share were withheld by the company to satisfy his tax obligations upon vesting of previously granted restricted stock units.
After this tax-withholding disposition, Navratil directly holds 76,694 shares of common stock, which includes 41,561 restricted stock units that have not yet vested or been delivered to him.
Glaukos Corp (GKOS) Chairman & CEO Thomas William Burns reported a tax-related share disposition on March 5, 2026. The company withheld 1,098 shares of common stock at $112.10 per share to cover his tax obligations when previously granted restricted stock units vested.
After this withholding, he directly owns 250,464 common shares, which includes 79,828 restricted stock units that have not yet vested or been delivered. He also reports indirect ownership through several Burns family and charitable trusts, including the Burns Family Trust, Burns Annuity Trust, Burns Charitable Remainder Trust, and two irrevocable trusts, each with disclosed share balances as of the same date.
Glaukos Corporation furnished a new Investor Presentation as Exhibit 99.1 to a current report. The company states it may use this March 2026 presentation from time to time in meetings with investors and other stakeholders, and it will be available on the investor page of its website.
The company clarifies that the Investor Presentation and related disclosure under Item 7.01 are being provided under Regulation FD and are not deemed filed under Section 18 of the Exchange Act or incorporated into other securities law filings unless specifically referenced.
Glaukos Corp chairman and CEO Thomas William Burns reported a tax-withholding share disposition related to restricted stock units. On February 24, 2026, 4,059 shares of common stock were withheld by Glaukos at $119.17 per share to satisfy his tax obligations upon RSU vesting.
After this transaction, Burns directly owns 251,562 shares of Glaukos common stock, which the footnotes state include 81,912 unvested restricted stock units. He also reports additional indirect ownership through multiple Burns family-related trusts, each holding separate blocks of Glaukos shares.
Glaukos Corp’s chief development officer, Tomas Navratil, reported a small tax-related share disposition. On the vesting of previously granted restricted stock units, 396 shares of common stock were withheld by the company at $119.17 per share to cover tax obligations. After this withholding, Navratil directly holds 77,055 shares of common stock, including 42,588 restricted stock units that are granted but not yet vested or delivered.
GLAUKOS Corp President and COO Joseph E. Gilliam reported a Form 4 showing a tax-related share disposition tied to vesting equity awards. On this Form 4, 1,057 shares of common stock were withheld by the company at $119.17 per share to satisfy his tax withholding obligations when restricted stock units granted on March 18, 2021 vested and were delivered.
After this tax-withholding disposition, Gilliam directly owned 91,309 shares of GLAUKOS common stock, which includes 60,661 restricted stock units that have not yet vested or been delivered. This reflects an administrative equity and tax event rather than an open-market stock sale.
GLAUKOS Corp director Aimee S. Weisner reported multiple equity transactions in company stock. She exercised a stock option for 15,000 shares of common stock at an exercise price of $24.69 per share, then reported open-market sales totaling 15,000 shares at weighted average prices between $115.69 and $118.56 across several trade blocks. She also reported bona fide gifts of 980 shares from her direct holdings and 980 shares transferred to the Saeman-Weisner Family Trust. After these transactions, she directly owned 18,806 shares and indirectly owned 29,505 shares through the Saeman-Weisner Family Trust, which includes 2,731 restricted stock units noted in the footnotes.
Glaukos Corporation is an ophthalmic pharmaceutical and medical technology company focused on glaucoma, corneal disorders and retinal disease. Its core products include the iStent micro‑scale glaucoma devices, iDose TR long‑duration intracameral implant approved in December 2023, and Photrexa/iLink corneal cross‑linking therapies.
The FDA approved Epioxa iLink epi‑on for keratoconus in October 2025, with commercial launch planned in the first half of 2026. In 2025, about 83% of net sales came from glaucoma products (iStent family, iDose TR and accessories) and 17% from iLink therapies. The company is advancing multiple platforms, including iLution transdermal creams and Retinal XR sustained‑release intravitreal drugs, and invests heavily in R&D and international expansion.
Key risks highlighted include dependence on successful commercialization of iDose TR and Epioxa, exposure to macroeconomic and geopolitical volatility, manufacturing and supply disruptions, ongoing operating losses since inception, complex global regulatory and reimbursement regimes, cybersecurity and data‑privacy obligations, and intense competition from larger ophthalmic device and drug companies.